Stephen Demarest

Stephen Demarest has 18 years of antibody and multi-specific protein development experience in both Biotech and Pharma. He contributed to >10 molecules that reached IND-enabling studies and managed departments that moved many more. Stephen's career began at Syngenta and Diversa before moving to Biogen Idec where he became Associate Director of Protein Sciences. At Lilly, Stephen was the head of Lilly’s Protein Engineering and Computational Biotherapeutics Departments, liaison to Immunology and Oncology, and the Diversity and Inclusion Champion for Biotech. Stephen is a co-developer of Lilly’s Orthomab bispecific technology with partners at UNC Chapel Hill and used the technology to bring many bispecifics into development including with external partners. The technology has also been licensed by AbCellera. He has >45 publications and is an inventor on >20 granted patents and applications.

Stephen received his BS and PhD in Chemistry from Texas A&M University and SUNY Stony Brook, respectively, and performed postdoctoral studies at The Scripps Research Institute.